{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:36:47Z","timestamp":1792431407929,"version":"4.5.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1093\/jnci\/dju089","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T05:01:36Z","timestamp":1400562096000},"source":"Crossref","is-referenced-by-count":129,"title":["Phase I\/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses"],"prefix":"10.1093","volume":"106","author":[{"given":"Jung-Min","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Minasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo Anne","family":"Zujewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minshu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuping","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan M.","family":"Sissung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford J.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise C.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,5,19]]},"reference":[{"issue":"1","key":"key\n\t\t\t\t20170702071050_CIT0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0378-5122(00)00188-2","article-title":"DNA repair mechanisms","volume":"38","author":"Hoeijmakers","year":"2001","journal-title":"Maturitas"},{"issue":"1","key":"key\n\t\t\t\t20170702071050_CIT0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543780802525324","article-title":"Development of PARP inhibitors in oncology","volume":"18","author":"Rodon","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"18","key":"key\n\t\t\t\t20170702071050_CIT0003","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-10-0526","article-title":"Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer","volume":"16","author":"Annunziata","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"key\n\t\t\t\t20170702071050_CIT0004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajh.2830370402","article-title":"Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma","volume":"37","author":"Tomoda","year":"1991","journal-title":"Am J Hematol"},{"issue":"1","key":"key\n\t\t\t\t20170702071050_CIT0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/AOG.0b013e3181c2d294","article-title":"High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer","volume":"115","author":"Barnett","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"7","key":"key\n\t\t\t\t20170702071050_CIT0006","first-page":"1163","article-title":"Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer","volume":"2","author":"Bieche","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"3","key":"key\n\t\t\t\t20170702071050_CIT0007","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"key\n\t\t\t\t20170702071050_CIT0008","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7035","key":"key\n\t\t\t\t20170702071050_CIT0009","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"5340","key":"key\n\t\t\t\t20170702071050_CIT0010","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","article-title":"Integrating genetic approaches into the discovery of anticancer drugs","volume":"278","author":"Hartwell","year":"1997","journal-title":"Science"},{"issue":"2","key":"key\n\t\t\t\t20170702071050_CIT0011","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMe0903044","article-title":"Synthetic lethality\u2014a new direction in cancer-drug development","volume":"361","author":"Iglehart","year":"2009","journal-title":"N Engl J Med"},{"issue":"7035","key":"key\n\t\t\t\t20170702071050_CIT0012","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"4","key":"key\n\t\t\t\t20170702071050_CIT0013","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"key\n\t\t\t\t20170702071050_CIT0014","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"15","key":"key\n\t\t\t\t20170702071050_CIT0015","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9737","key":"key\n\t\t\t\t20170702071050_CIT0016","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"issue":"9737","key":"key\n\t\t\t\t20170702071050_CIT0017","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"key\n\t\t\t\t20170702071050_CIT0018","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"issue":"21","key":"key\n\t\t\t\t20170702071050_CIT0019","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"key\n\t\t\t\t20170702071050_CIT0020","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","article-title":"Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","volume":"22","author":"Vencken","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"key\n\t\t\t\t20170702071050_CIT0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","volume":"26","author":"Chetrit","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"key\n\t\t\t\t20170702071050_CIT0022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/157340606775197697","article-title":"Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells","volume":"2","author":"Nguewa","year":"2006","journal-title":"Med Chem"},{"issue":"4","key":"key\n\t\t\t\t20170702071050_CIT0023","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/1078-0432.CCR-10-1382","article-title":"Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts","volume":"17","author":"Kortmann","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170702071050_CIT0024","author":"BayesMendel Lab"},{"issue":"3","key":"key\n\t\t\t\t20170702071050_CIT0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"key\n\t\t\t\t20170702071050_CIT0026","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1158\/1078-0432.CCR-08-0214","article-title":"Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts","volume":"14","author":"Kinders","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"key\n\t\t\t\t20170702071050_CIT0027","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-07-2206","article-title":"Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1","volume":"7","author":"Gao","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"key\n\t\t\t\t20170702071050_CIT0028","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/cncr.27916","article-title":"Feasibility and safety of sequential research-related tumor core biopsies in clinical trials","volume":"119","author":"Lee","year":"2013","journal-title":"Cancer"},{"issue":"6","key":"key\n\t\t\t\t20170702071050_CIT0029","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1074\/mcp.M112.026427","article-title":"Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort","volume":"12","author":"Azad","year":"2013","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"key\n\t\t\t\t20170702071050_CIT0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cncr.22757","article-title":"A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling","volume":"110","author":"Posadas","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"key\n\t\t\t\t20170702071050_CIT0031","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/cncr.22545","article-title":"A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer","volume":"109","author":"Posadas","year":"2007","journal-title":"Cancer"},{"issue":"22","key":"key\n\t\t\t\t20170702071050_CIT0032","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1002\/pmic.200700484","article-title":"Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays","volume":"7","author":"Winters","year":"2007","journal-title":"Proteomics"},{"issue":"2","key":"key\n\t\t\t\t20170702071050_CIT0033","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-09-1979","article-title":"Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells","volume":"16","author":"Rasool","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170702071050_CIT0034","author":"MD Anderson Cancer Center"},{"issue":"3","key":"key\n\t\t\t\t20170702071050_CIT0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bjc.6600431","article-title":"Reduced apoptotic levels in squamous but not basal cell carcinomas correlates with detection of cutaneous human papillomavirus","volume":"87","author":"Jackson","year":"2002","journal-title":"Br J Cancer"},{"issue":"4","key":"key\n\t\t\t\t20170702071050_CIT0036","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"issue":"12","key":"key\n\t\t\t\t20170702071050_CIT0037","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1172\/JCI74035","article-title":"Predicting time to ovarian carcinoma recurrence using protein markers","volume":"123","author":"Yang","year":"2013","journal-title":"J Clin Invest"},{"issue":"22","key":"key\n\t\t\t\t20170702071050_CIT0038","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1158\/1078-0432.CCR-13-1975","article-title":"Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer","volume":"19","author":"Cardnell","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"key\n\t\t\t\t20170702071050_CIT0039","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2013.389","article-title":"Deleterious BRCA1\/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions","volume":"109","author":"Moon","year":"2013","journal-title":"Br J Cancer"},{"issue":"9","key":"key\n\t\t\t\t20170702071050_CIT0040","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"issue":"15","key":"key\n\t\t\t\t20170702071050_CIT0041","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"key\n\t\t\t\t20170702071050_CIT0042","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-11-2821","article-title":"A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas","volume":"18","author":"Kummar","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170702071050_CIT0043","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5001","article-title":"Olaparib plus paclitaxel plus carboplatin (P\/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study","volume":"30","author":"Oza","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"key\n\t\t\t\t20170702071050_CIT0044","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-11-2425","article-title":"A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors","volume":"18","author":"Rajan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170702071050_CIT0045","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5505","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)","volume":"31","author":"Ledermann","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"key\n\t\t\t\t20170702071050_CIT0046","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1535-7163.MCT-11-0272","article-title":"BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin","volume":"10","author":"Safra","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"key\n\t\t\t\t20170702071050_CIT0047","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov"},{"issue":"24","key":"key\n\t\t\t\t20170702071050_CIT0048","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","article-title":"A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer","volume":"16","author":"Graeser","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"22","key":"key\n\t\t\t\t20170702071050_CIT0049","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"29","key":"key\n\t\t\t\t20170702071050_CIT0050","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1200\/JCO.2010.30.1010","article-title":"BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors","volume":"28","author":"Veeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"44","key":"key\n\t\t\t\t20170702071050_CIT0051","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"key\n\t\t\t\t20170702071050_CIT0052","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2008.19.7681","article-title":"Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies","volume":"27","author":"Kummar","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"key\n\t\t\t\t20170702071050_CIT0053","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4161\/cc.9.6.11035","article-title":"The AMPK-FoxO3A axis as a target for cancer treatment","volume":"9","author":"Chiacchiera","year":"2010","journal-title":"Cell Cycle"},{"issue":"4","key":"key\n\t\t\t\t20170702071050_CIT0054","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ncb1709","article-title":"Functional interaction between FOXO3a and ATM regulates DNA damage response","volume":"10","author":"Tsai","year":"2008","journal-title":"Nat Cell Biol"},{"key":"key\n\t\t\t\t20170702071050_CIT0055","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ncomms2008","article-title":"FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage","volume":"3","author":"Chung","year":"2012","journal-title":"Nat Commun"},{"issue":"9","key":"key\n\t\t\t\t20170702071050_CIT0056","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-10-2334","article-title":"Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer","volume":"17","author":"Pettersson","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"9","key":"key\n\t\t\t\t20170702071050_CIT0057","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjc.6605044","article-title":"Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity","volume":"100","author":"Coleman","year":"2009","journal-title":"Br J Cancer"},{"issue":"3","key":"key\n\t\t\t\t20170702071050_CIT0058","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2013.06.019","article-title":"Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies","volume":"130","author":"Ross","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170702071050_CIT0059","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ygyno.2006.09.004","article-title":"Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer","volume":"104","author":"Sillanpaa","year":"2007","journal-title":"Gynecol Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/106\/6\/dju089\/17934814\/dju089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T16:53:05Z","timestamp":1597855985000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/dju089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,19]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,5,19]]},"published-print":{"date-parts":[[2014,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/dju089","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5,19]]}}}